Ovarian cancer is associated with height and, among never-users of hormone therapy, body mass index.
The small-molecule MEK inhibitor selumetinib was found to be active in the treatment of women with recurrent low-grade serous ovarian or peritoneal carcinoma
African-American are also nearly twice as likely to have an abnormal Pap smear.
Researchers found that the rate of endometrial cancer among women who had taken bisphosphonates was approximately half that of women who had never taken the medication (9.6 vs. 18.7 per 10,000 person years). The effect was more significant with less-aggressive cancers.
Olaparib as maintenance treatment significantly improved progression-free survival in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer.
The cervical-cancer screening program used by the Netherlands is as effective as the screening protocol used in the United States, producing similar cervical cancer mortality rates in spite of less screening.
Accumulation of telomeric allelic imbalance predicts sensitivity to cisplatin.
In what is believed to be the first reported case of dermatomyositis-associated panniculitis in the setting of ovarian adenocarcinoma and a recurrent malignancy, a 63-year-old woman sustained clinical improvement following treatment with prednisone and oral methotrexate.
(ChemotherapyAdvisor) – New guidelines from the United States Preventive Services Task Force (USPSTF) recommend screening for cervical cancer in women 21-65 years of age with cytology (Papanicolaou smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, a combination of cytology with human papillomavirus (HPV) testing every 5 years.